According to Cardiac Insight, early physician and patient experiences with Cardea SOLO are confirming the FDA-cleared cardiac device, designed to streamline arrhythmia detection in patients, is providing a higher standard of ambulatory cardiac care and efficiencies in cardiac practices.
Cardiac Insight said that Cardea SOLO's compact, cable-free ECG device records every heart beat, yet offers longer, comfortable and nonintrusive diagnostic wear time that improves a patient's experience and compliance, especially when compared to a traditional 48-hour ECG monitor.
Its standalone plug-and-play ECG arrhythmia analysis and reporting system seamlessly integrates into a cardiology or other medical clinic's existing operational infrastructure, keeping patient data secure and available immediately for review.
Cardea SOLO is small, lightweight (about the weight of three quarters), water-resistant and single-use disposable.
In September, Cardiac Insight announced another infusion of investment into its active C-1 funding round and development of a Scientific advisory board.
The physicians, nurses and medical assistants of Cardiology Partners have been providing cardiac care for patients in the Mansfield/Arlington, Texas area since 1979.
As the largest cardiology practice in Mansfield, Cardiology Partners offers patient care with a range of in-office treatment options and privileges at all major hospitals in the Mansfield/Arlington area.
Cardiac Insight is a US developer of advanced body-worn digital health care information devices for cardiology, respiratory and other complex disease states.
The company was founded in 2008 and is based in Kirkland, Washington.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
D3 Bio announces Series A+ Round completion to advance innovative oncology pipeline
Dizal's sunvozertinib receives US FDA Breakthrough Therapy Designation
Merck launches Phase 3 trial of MK-1084 and KEYTRUDA combination in metastatic NSCLC
Trevi Therapeutics names new vice president of Clinical Development
Personalis validates NeXT Personal test for ultra-sensitive MRD detection
Merck reports lung cancer trial failed to meet endpoints
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib